1 – 15 of 34
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Regional variation i användningen av TTF vid glioblastombehandling
(
- Contribution to journal › Article
-
Mark
Do young adults with cancer receive information about treatment-related impact on sex life? Results from a population-based study
(
- Contribution to journal › Article
- 2022
-
Mark
Prevalence and risk factors for sexual dysfunction in young women following a cancer diagnosis–a population-based study
(
- Contribution to journal › Article
- 2021
-
Mark
Fertility-related information received by young women and men with cancer–a population-based survey
(
- Contribution to journal › Article
-
Mark
LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes
(
- Contribution to journal › Article
- 2019
-
Mark
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours : A Dose-Escalation Study
(
- Contribution to journal › Article
- 2018
-
Mark
Disparities in colorectal cancer between Northern and SouthernSweden–a report from the new RISK North database
(
- Contribution to journal › Article
- 2017
-
Mark
Functional germline variants in driver genes of breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
LRIG1 is a prognostic biomarker in non-small cell lung cancer
(
- Contribution to journal › Article
-
Mark
Inbreeding and homozygosity in breast cancer survival.
(
- Contribution to journal › Article
- 2014
-
Mark
Systematic pathway enrichment analysis of a genome-wide association study on breast cancer survival reveals an influence of genes involved in cell adhesion and calcium signaling on the patients' clinical outcome.
(
- Contribution to journal › Article
- 2013
-
Mark
The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer
(
- Contribution to journal › Article
- 2012
-
Mark
Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer
(
- Contribution to journal › Article
-
Mark
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival
(
- Contribution to journal › Article